MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41598-025-19214-0

Медицинская библиотека · Scientific reports · 2025

Rituximab-induced long-term remission in childhood-onset, uncomplicated, frequently relapsing or steroid-dependent nephrotic syndrome: a randomized, placebo-controlled trial and a follow-up study.

Iijima Kazumoto, Sako Mayumi, Horinouchi Tomoko, Sakai Tomoyuki, Yamamura Tomohiko, Hamada Riku, Ohtsuka Yasufumi, Tanaka Seiji, Kamei Koichi, Tanaka Ryojiro, Kano Yuji, Kubota Takuo, Shima Yuko, Morohashi Tamaki, Inaba Aya, Fujinaga Shuichiro, Oka Masafumi, Kaito Hiroshi, Konishi Akihide, Nagano China, Nakanishi Koichi, Ishikura Kenji, Ito Shuichi, Nakamura Hidefumi, Ghiggeri Gian Marco, Mori Rintaro, Omori Takashi, Nozu Kandai, Japanese Study Group of Kidney Disease in Children JSKDC10 Study

СтатьяРандомизированное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

Rituximab maintains remission of complicated frequently relapsing or steroid-dependent nephrotic syndrome (FRNS/SDNS) by depleting peripheral B cells, but most patients eventually experience relapses after B cell recovery. We performed a multicenter, double-blind, randomized, placebo-controlled trial to assess rituximab's efficacy and safety for childhood-onset uncomplicated FRNS/SDNS (without prior treatment with glucocorticoid-sparing immunosuppressive agents) with a follow-up study to assess rituximab's long-term effect after B cell recovery. Patients were randomly assigned to receive either rituximab (375 mg/m2, maximum 500 mg, once weekly for 2 weeks) or placebo. The primary endpoint was the relapse-free period. Of 43 randomized patients, 40 received the intervention (18 rituximab, 22 placebo). The relapse-free period during the 1-year trial was significantly longer in the rituximab vs. placebo groups (median: 285 vs. 81 days; p < 0.001). Infusion reactions were more frequent in the rituximab group (p < 0.001), with no difference in adverse events incidence between the groups. Interestingly, the follow-up study demonstrated markedly higher 3-year cumulative relapse-free survival probability without further treatments in the rituximab vs. placebo groups (38% vs. 9%). A mini-systematic review with meta-analyses supported the findings. Rituximab is effective and well-tolerated, potentially leading to long-term remission with substantially high rates after B cell recovery for childhood-onset uncomplicated FRNS/SDNS.Trial registration JSKDC10, Clinical Trials Registry ID: jRCT1091220380; JSKDC10 follow-up study, Clinical Trials Registry ID: jRCT1050230024.

Для цитирования: Iijima Kazumoto, Sako Mayumi, Horinouchi Tomoko, Sakai Tomoyuki, Yamamura Tomohiko, Hamada Riku, Ohtsuka Yasufumi, Tanaka Seiji, Kamei Koichi, Tanaka Ryojiro, Kano Yuji, Kubota Takuo, Shima Yuko, Morohashi Tamaki, Inaba Aya, Fujinaga Shuichiro, Oka Masafumi, Kaito Hiroshi, Konishi Akihide, Nagano China, Nakanishi Koichi, Ishikura Kenji, Ito Shuichi, Nakamura Hidefumi, Ghiggeri Gian Marco, Mori Rintaro, Omori Takashi, Nozu Kandai, Japanese Study Group of Kidney Disease in Children JSKDC10 Study. Rituximab-induced long-term remission in childhood-onset, uncomplicated, frequently relapsing or steroid-dependent nephrotic syndrome: a randomized, placebo-controlled trial and a follow-up study.. Scientific reports. 2025. DOI: 10.1038/s41598-025-19214-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.